Pregnancy outcome in Hispanic patients with unexplained positive triple marker screening for Down syndrome

Abstract

Hispanic patients with unexplained positive triple marker screen for Down syndrome do not appear to be at increased risk for adverse pregnancy outcomes.

First‐ and second‐trimester tests to predict stillbirth in unselected pregnant women: a systematic review and meta‐analysis

“…Of these, 214 were excluded, the primary reason being the inclusion of both miscarriages and stillbirths or neonatal deaths and stillbirths in the mortality outcome measure or stillbirth in a composite outcome measure (21%), which did not allow the predictive accuracy of tests for stillbirths alone to be calculated. Seventy‐one studies (50 cohort and 21 case–control studies), assessing a total of 16 single and five combined tests, met the inclusion criteria (see Figure S1). Box 1 lists the first‐trimester and second‐trimester tests to predict stillbirth in unselected pregnant women that were identified in the review.…”

“…The sample size in the cohort studies ranged from 110 to 718 011 (median 9672) women. The number of cases and controls enrolled in case–control studies ranged from 33 to 707, and 100 to 15 689, respectively. The prevalence rates for stillbirth in cohort studies ranged between 0.6 and 16.4 per 1000 births (median 4.6 per 1000 births).…”

“…A large cohort study reported an antepartum stillbirth prevalence of 3.5 per 1000 births . Thirty‐four studies provided predictive accuracy data on five fetoplacental peptides (18 on alphafetoprotein [ α ‐FP], 15 on human chorionic gonadotrophin [hCG], three on unconjugated estriol [uE 3 ], seven on pregnancy‐associated plasma protein A [PAPP‐A], and one on inhibin A); 19 on six ultrasound imaging‐related tests (seven on uterine artery Doppler velocimetry, four each on nuchal translucency and suboptimal fetal growth, two on echogenic bowel, and one each on short femur and ductus venosus); 12 on five combinations of tests (three on first‐trimester screening for Down syndrome, five on second‐trimester screening for Down syndrome, one on first‐ and second‐trimester sequential integrated screening for Down syndrome and three on multivariable prediction models,); four on thyroid function‐related tests; two each on maternal haemoglobin levels and 25‐hydroxyvitamin D serum levels; and one on cervicovaginal infection . Few studies reported estimates of the predictive accuracy for stillbirths according to the timing of death, gestational age at birth, presumed cause of death or associated medical/obstetric disorder .…”

Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: Systematic review and meta-analysis

“…There were 86 included studies for SGA [ 7 , 9 , 37 , 39 , 47 , 51 , 53 - 55 , 57 , 59 - 61 , 64 - 67 , 69 , 74 , 76 - 141 ], reporting on 382,005 women (20339 cases of SGA, incidence 5.32%). Among these studies, there were 61 cohort studies and 25 case control studies [ 53 , 55 , 76 , 77 , 82 - 85 , 88 , 89 , 94 , 96 , 97 , 104 , 113 , 116 , 119 , 123 - 125 , 130 , 131 , 133 , 135 , 140 ]. Thirty-one studies were prospective, 17 retrospective and 38 of unclear design.…”

False-Positive Maternal Serum Screens in the Second Trimester as Markers of Placentally Mediated Complications Later in Pregnancy: A Systematic Review and Meta-Analysis

“…The 16 studies published in September 2019 represent 68515 singleton pregnancies globally [24][25][26][43][44][45][46][47][48][49][50][51][52][53][54][55]. Five studies examined second-trimester double-marker screening (AFP and hCG), 10 studies examined triple-marker screening (AFP, hCG, and uE3), and one study examined quadruple-marker screening (AFP, hCG, uE3, and DIA) (Table 1).…”